Although the occurrence of TP53 mutations could be a potential mechanism of resistance to chemotherapy-induced RP/MDM2/p53 pathway activation, the majority of DLBCL patients display wild-type (WT) TP53,12 thus indicating that alternative mechanisms of resistance could explain the failure of anthracycline-containing regimens in a significant fraction of cases.13 The gene discussed is MDM2; the disease is diffuse large B-cell lymphoma.